CNH publishes 2026 Annual General Meeting agenda Basildon, March 25, 2026 CNH Industrial (NYSE: CNH) announced today that it has published its notice of the 2026 Annual General Meeting of Shareholders (“AGM”) and proxy statement. The AGM will be held on May 8, 2026, in Amsterdam, The Netherlands. The proceedings can also be followed via a live webcast on the Company’s website (www.cnh.com). The Company’s AGM materials and instructions for voting and submitting questions in advance of the meeting, together with those on how to follow the AGM remotely are available on the Company’s website at www.cnh.com, where they can be viewed and downloaded. Shareholders may request a hard copy of these materials, which include CNH Industrial’s audited financial statements, free of charge, through the contacts below. The Board of Directors has...

TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on the development of natural, plant-based active ingredients, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2025. All amounts in this press release are in U.S. dollars. Corporate Update Following the reconstitution of the Company’s board of directors (the “Board”) on May 30, 2025, the Company has undertaken a series of initiatives designed to follow through on the commitment of the reconstituted Board to actively review COSCIENS’ prospects and opportunities, and to take the actions necessary to best position COSCIENS to create value for shareholders. Notably, during the second half of 2025, the Company executed...

Second Quarter of Fiscal 2026 Highlights*Net sales were $155 million, a 6% increase compared to the prior year, with a 2% increase in organic sales1. IT&S Product sales increased 6% organically, the highest growth in 10 quarters. Operating profit margin was 16.2% and adjusted operating profit margin was 19.0%. Net earnings were $16.3 million, or $0.31 per diluted share. Adjusted net earnings were $20.3 million, or $0.39 per diluted share. Adjusted EBITDA was $33.0 million and adjusted EBITDA margin was 21.3%. Year-to-date operating cash flow was $29 million, up from $16 million in the prior year. Returned approximately $51 million to shareholders through share repurchases. Won a five-year service contract with a major UK oil & gas customer. Launched six new products at ConExpo, including the recently acquired Hydra Pac diesel...

CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) — Integral Metals Corp. (CSE: INTG | OTC: ITGLF | FSE: ZK9) (the “Company” or “Integral”) is pleased to announce the appointment of Leo Power to its Board of Directors, effective immediately. Mr. Power is an accomplished entrepreneur based in Newfoundland and Labrador, with extensive senior leadership experience across the energy and natural resource sectors. His background spans operations, investment, and corporate governance, providing a well-rounded perspective on advancing and scaling resource-focused companies. Mr. Power currently serves as Chief Executive Officer of Poseidon Energy Corp. and is a director of Q2 Metals Corp. He holds a joint MBA from the Kellogg School of Management and the Schulich School of Business, as well as a Master of Oil and Gas Studies from Memorial...

Koné project construction on-budget and ahead of schedule • Strong continued exploration focus • Robust liquidity sources CONSTRUCTION ACTIVITIESRapid progress achieved with +9.0 million hours worked to date, with more than 3,000 employees and contractors on-site Well on track for first gold pour in late Q4-2026 through the oxide circuit and on budget with $572.8 million of capital committed as at today, representing approximately 65% of the total upfront capital expenditure Key process plant achievements include completion of all CIL tanks and ball mill shell installation, oxide sizer completion, foundation concrete pours for pre-leach and tailings thickeners, and advancement of the hard-rock comminution circuit Other key infrastructure is well advanced including the full operation of the river abstraction and water storage facilities,...

– FDA Grants IND Clearance for SER-252– SER-252 Phase 1b Trial Initiated– Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. “This past year was defined by execution, advancing SER-252 from IND filing through FDA clearance, into the clinic while strengthening our balance sheet to support the clinical milestones ahead,” said Steve Ledger, CEO of Serina. “With the first patient dosed in our registrational trial in advanced Parkinson’s...